Coherus Oncology, Inc. (CHRS): Gross Profit

Revenue minus cost of revenue for the same annual period and currency, computed by TickerFacts from the filed figures. The issuer may report gross profit or margin on a different basis.

Computed by TickerFacts from revenue minus cost of revenue. This may differ from the issuer's reported gross profit or margin; check the revenue and cost definitions.

Partial revenue. In this company's filings, net income for the year ended 2025-12-31 is larger than reported revenue. The revenue it tags covers only part of its income (banks and REITs often tag only fee income this way, leaving out interest or rent), so it is not the company's whole top line. Margins on it are not computed, and it is left out of revenue rankings.

$28.36M
Year ended 2025-12-31
$35.11M
Trailing 12 months to 2026-06-30
-41.4%
3-year compound annual growth
-42.2%
5-year compound annual growth
$438.16M2020-12-31: $438.16M2021-12-31: $268.96M2022-12-31: $140.96M2023-12-31: $98.25M2024-12-31: $17.66M2025-12-31: $28.36M$28.36M
2020-12-31 Gross Profit (USD) 2025-12-31
Period endedGross ProfitChange YoYSource filing
2025-12-31$28.36M+60.6%2026-03-09, From 2025-01-01
2024-12-31$17.66M-82.0%2026-03-09, From 2024-01-01
2023-12-31$98.25M-30.3%2025-03-17, From 2023-01-01
2022-12-31$140.96M-47.6%2025-03-17, From 2022-01-01
2021-12-31$268.96M-38.6%2024-03-15, From 2021-01-01
2020-12-31$438.16Mn/a2023-03-06, From 2020-01-01